DAY 2: Friday, May 8th
SESSION 2: TREATMENT OF PV IN 2026
Chairs: M. Krauth, T. Sacha
| 09:30 - 09:45 | Welcome in the name of Gemfin | A. Álvarez-Larrán |
| 09:45 - 10:10 | How successful are we in meeting treatment goals? | S. Koschmieder |
| 10:10 - 10:35 | Changing needs throughout the lifespan | H. Gisslinger |
| 10:35 - 10:40 | Poll | |
| 10:40 - 11:20 | Is there still a place for non-disease-modifying therapies? | PRO: A. Lucchesi CON: F. Heidel |
| 11:20 - 11:30 | Poll | |
| 11:30 - 11:55 | Can we prevent recurring thromboses? | H. Al-Ali |
| 11:55 - 13:30 | Lunch Break |
Chairs: J. Schwarz, M. Griesshammer
| 13:30 - 13:55 | How to conduct a real-world study | L. Cadmann-Davies |
| 13:55 - 14:20 | Final results of BESREMi-PASS study | V. Buxhofer-Ausch |
| 14:20 - 14:45 | Pregnancy | M. Sobas |
| 14:45 - 15:15 | Break |
SESSION 3: EMERGING TOPICS IN HEMATOLOGY
Chairs: E. Abruzzese, P. Žák
| 15:15 - 15:45 | Keynote lecture: Disease continuum from early MF to combinations | M. F. McMullin |
| 15:45 - 16:05 | AML | K. Gleixner |
| 16:05 - 16:30 | Experience with Europe’s first CHIP clinics | C. Lykkegard Andersen |